Moderna's mRNA vaccine cocktail passes early safety check
NCT ID NCT05397223
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and immune response of several Moderna mRNA vaccines for COVID-19, seasonal flu, RSV, and CMV in 308 healthy adults aged 18 to 75. Researchers monitored side effects and measured antibody levels after vaccination. The goal was to ensure the vaccines are safe and trigger a strong immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Benchmark Research
Austin, Texas, 78705, United States
-
CenExel
Hollywood, Florida, 33024, United States
-
DM Clinical Research- Texas Center for Drug Development
Houston, Texas, 77081, United States
-
Johnson County Clinical Trials
Lenexa, Kansas, 66219, United States
-
Meridian Clinical Research
Savannah, Georgia, 31406, United States
-
Meridian Clinical Research
Sioux City, Iowa, 51106, United States
-
Meridian Clinical Research
Lincoln, Nebraska, 68510, United States
-
Tekton Research, Inc
Austin, Texas, 78745, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill keep High-Risk COVID-19 patients out of the hospital?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Millions of vaccine records scoured for rare side effects
- Could a vaccine given during pregnancy shield infants from a deadly virus?
- Scientists probe why lung disease raises COVID-19 risk
- New rapid test could spot COVID and flu in minutes